RT Journal Article
SR Electronic
T1 Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.25.21257505
DO 10.1101/2021.05.25.21257505
A1 Varona, José F.
A1 Landete, Pedro
A1 Lopez-Martin, Jose A.
A1 Estrada, Vicente
A1 Paredes, Roger
A1 Guisado-Vasco, Pablo
A1 de Orueta, Lucía Fernández
A1 Torralba, Miguel
A1 Fortún, Jesús
A1 Vates, Roberto
A1 Barberán, José
A1 Clotet, Bonaventura
A1 Ancochea, Julio
A1 Carnevali, Daniel
A1 Cabello, Noemí
A1 Porras, Lourdes
A1 Gijón, Paloma
A1 Monereo, Alfonso
A1 Abad, Daniel
A1 Zúñiga, Sonia
A1 Sola, Isabel
A1 Rodon, Jordi
A1 Izquierdo-Useros, Nuria
A1 Fudio, Salvador
A1 Pontes, María José
A1 Rivas, Beatriz de
A1 Girón de Velasco, Patricia
A1 Sopesén, Belén
A1 Nieto, Antonio
A1 Gómez, Javier
A1 Avilés, Pablo
A1 Lubomirov, Rubin
A1 White, Kris M.
A1 Rosales, Romel
A1 Yildiz, Soner
A1 Reuschl, Ann-Kathrin
A1 Thorne, Lucy G.
A1 Jolly, Clare
A1 Towers, Greg J.
A1 Zuliani-Alvarez, Lorena
A1 Bouhaddou, Mehdi
A1 Obernier, Kirsten
A1 Enjuanes, Luis
A1 Fernández-Sousa, Jose M.
A1 ,
A1 Krogan, Nevan J.
A1 Jimeno, José M.
A1 García-Sastre, Adolfo
YR 2021
UL http://medrxiv.org/content/early/2021/05/25/2021.05.25.21257505.abstract
AB Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A). We evaluated a model of intervention with plitidepsin in hospitalized COVID-19 adult patients where three doses were assessed (1.5, 2 and 2.5 mg/day for 3 days, as a 90-minute intravenous infusion) in 45 patients (15 per dose-cohort). Treatment was well tolerated, with only two Grade 3 treatment-related adverse events observed (hypersensitivity and diarrhea). The discharge rates by Days 8 and 15 were 56.8% and 81.8%, respectively, with data sustaining dose-effect. A mean 4.2 log10 viral load reduction was attained by Day 15. Improvement in inflammation markers was also noted in a seemingly dose-dependent manner. These results suggest that plitidepsin impacts the outcome of patients with COVID-19.One-Sentence Summary Plitidepsin, an inhibitor of SARS-Cov-2 in vitro, is safe and positively influences the outcome of patients hospitalized with COVID-19.Competing Interest StatementVicente Estrada has received personal fees from Janssen, Gilead, and ViiV and grants from MSD. Roger Paredes has participated in Advisory Boards from Gilead, MSD, ViiV Healthcare and Theratechnologies. Miguel Torralba has received consulting fees as a member of Advisory Committee and honoraria and speaking fees from Gilead, Janssen, MSD and ViiV Companies. Jesus Fortun has participated in scientific events and received consulting or speaking fees or oral presentations from: Pfizer, Gilead, MSD, Astellas, Novartis and Roche. Julio Ancoechea has received fees for scientific consulting and/or speaking from Actelion, Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, Carburos Medica, Chiesi, Faes Farma, Ferrer, GlaxoSmithKline, InterMune, Linde Healthcare, Menarini, MSD, Mundipharma, Novartis, Pfizer, Roche, Rovi, Sandoz, Takeda and Teva. Isabel Sola, Sonia Zuniga and Luis Enjuanes hold a Technology Support contract with Pharmamar. Nuria Izquierdo-Useros is inventor of a patent of Plitidepsin (EP20382821.5). The Krogan Laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. Nevan Krogan has consulting agreements with Maze Therapeutics and Interline Therapeutics, and is a shareholder of Tenaya Therapeutics. Jose M. Fernandez-Sousa is President and Founder of Pharmamar, S.A. (Madrid, Spain). Jose Jimeno holds stocks of Pangaea Oncology, has a non-remunerated role in the Scientific Advisory Board and holds stocks of Phosplatin Therapeutics; and is a full-time employee of PharmaMar, S.A. (Madrid, Spain).The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, PharmaMar, ImmunityBio, Accurius and Nanocomposix. Adolfo Garcia-Sastre has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak and Pfizer. A.G.-S. is inventor on patents and patent application on the use of antivirals for the treatment of virus infections, owned by the Icahn School of Medicine at Mount Sinai, New York. A patent application based on this work has been filed (EP20382821.5). Jose A. Lopez-Martin, Salvador Fudio, Maria Jose Pontes, Beatriz de Rivas, Belen Sopesen, Antonio Nieto, Javier Gomez, Patricia Giron de Velasco, Pablo Aviles and Rubin Lubomirov are employees and shareholders of PharmaMar, S.A (Madrid, Spain). Jose A. Lopez-Martin is a co-inventor of a patent for plitidepsin (WO2008135793A1). Jose M. Jimeno is a co-inventor on a patent for didemnin (WO99/42125) and on patents for aplidine (WO03/033013 and WO 2004/080421).Clinical TrialEudraCT #2020-001993-31 NCT #04382066Funding StatementThis study has been funded by Pharmamar, S.A. (Madrid, Spain). This work was supported by grants from the Government of Spain (PIE_INTRAMURAL_ LINEA 1 - 202020E079; PIE_INTRAMURAL_CSIC-202020E043). The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. We also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N.I.U. has non-restrictive funding from PharmaMar to study the antiviral effect of Plitidepsin. N.J.K. was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, and P01AI063302); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between UCSF, UCB, and GSK (#133122P); by the Roddenberry Foundation, and gifts from QCRG philanthropic donors. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement #HR0011-19-2-0020. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. This research was partly funded by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), by DARPA grant HR0011-19-2-0020, by supplements to NIAID grants U19AI142733, U19AI135972 and DoD grant W81XWH-20-1-0270, and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)), and anonymous donors to AG-S. S.Y. received funding from a Swiss National Foundation (SNF) Early Postdoc Mobility fellowship (P2GEP3_184202).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:HM Hospitals Drug Research Ethics Committee (CEIm HM Hospitales) 28660 - Boadilla del Monte (Madrid, Spain)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlitidepsin is available from PharmaMar for noncommercial use under an MTA. All relevant data are included within this manuscript and all materials other than plitidepsin are readily available upon request from the corresponding authors.